Pure Global AI
NCT06277765Not yet recruiting

Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis

A Randomized, Double Blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CM310 in Adolescent Patients With Moderate-to-severe Atopic Dermatitis
Keymed Biosciences Co.LtdPhase 3ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Atopic Dermatitis
Drug/Device/Intervention
CM310
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Keymed Biosciences Co.Ltd
Location
Beijing, China
Timeline & enrollment
Phase
Phase 3
Start date
May 30, 2024
End date
May 30, 2025
Enrollment
180 participants
Primary outcome

Proportion of subjects achieving EASI-75 at week 18

Summary

This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to
 evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in children patients with
 moderate-to-severe atopic dermatitis.

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06277765
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06277765 through Pure Global AI's free database. This Phase 3 trial is sponsored by Keymed Biosciences Co.Ltd and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 180 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.